ORCID as entered in ROS

Select Publications
2018, 'ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 196 - 196, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200343&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2018, 'Avelumab treatment of Australian patients with metastatic Merkel cell carcinoma (mMCC): Experience from an expanded access program (EAP)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 173 - 174, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200294&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Safe Delivery of Immunotherapy: A Private Cancer Physician's Perspective', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 88 - 89, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500078&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'FIRST-LINE CHEMOTHERAPY FOR EPITHELIAL OVARIAN CANCER: A NATIONAL APPROACH TO GUIDELINE RECOMMENDATIONS TO ENCOURAGE BEST PRACTICE', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 229 - 229, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500182&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'CIRCULATING BIOMARKERS AND OUTCOMES IN A PHASE 2 TRIAL OF FIRST-LINE EVEROLIMUS ALTERNATING WITH SUNITINIB FOR ADVANCED RENAL CELL CARCINOMA (ANZUP 0901-THE EVERSUN TRIAL)', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, pp. E65 - E65, http://dx.doi.org/10.1016/j.ejca.2014.03.245
,2014, 'Circulating biomarkers and outcomes in a single-arm phase II trial of first-line sunitinib alternating with everolimus for advanced renal cell carcinoma (aRCC): EVERSUN ANZUP trial 0901', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014, http://dx.doi.org/10.1200/jco.2014.32.4_suppl.428
,2014, 'EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014, http://dx.doi.org/10.1200/jco.2014.32.4_suppl.438
,2013, 'INTRODUCING THE NURSE PRACTITIONER ROLE TO IMPROVE REGIONAL ONCOLOGY PATIENT OUTCOMES', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 136 - 136, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800241&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'OVARIAN CANCER IN THE ELDERLY - THE ROLE OF SURGERY AND SYSTEMIC TREATMENT', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 67 - 67, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'PRACTICE PEARLS: WHAT IS DIFFERENT WHEN DEALING WITH THE OLDER PATIENT? A MEDICAL ONCOLOGIST'S PERSPECTIVE', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 62 - 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'SURVIVAL OF AUSTRALIAN WOMEN WITH EPITHELIAL OVARIAN CANCER - A POPULATION-BASED STUDY', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 81 - 81, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800072&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2012, 'Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, http://dx.doi.org/10.1200/jco.2012.30.18_suppl.lba5000
,2008, 'Renal function in the elderly', in Cancer Forum, pp. 11 - 16
,2007, 'Chemotherapy in elderly patients with renal insufficiency. Recommendations of the International Society of Geriatric Oncology (SIOG)', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, SPAIN, Barcelona, pp. 174 - 174, presented at 14th European Cancer Conference (ECCO 14), SPAIN, Barcelona, 23 September 2007 - 27 September 2007, http://dx.doi.org/10.1016/S1359-6349(07)70726-7
,2007, 'Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology (SIOG) clinical practice recommendations.', in EJC SUPPLEMENTS, PERGAMON-ELSEVIER SCIENCE LTD, SPAIN, Barcelona, pp. 175 - 175, presented at 14th European Cancer Conference (ECCO 14), SPAIN, Barcelona, 23 September 2007 - 27 September 2007, http://dx.doi.org/10.1016/S1359-6349(07)70729-2
,2004, 'Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with advanced epithelial ovarian cancer. A phase II trial of sequential doublets. (GO-FIRST).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, LA, New Orleans, pp. 457S - 457S, presented at 40th Annual Meeting of the American-Society-of-Clinical-Oncology, LA, New Orleans, 05 June 2004 - 08 June 2004, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000223512401812&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2002, 'Gastro-oesophageal complications in patients receiving cancer therapy: The role of proton pump inhibitors', in European Journal of Gastroenterology and Hepatology, pp. S17 - S21
,2024, 'Clinical impact of molecular profiling in the national prospective cohort Solving Unknown Primary Cancer (SUPER) study', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 42, presented at Special Clinical Science Symposia, ELECTR NETWORK, 29 May 2024 - 29 May 2024
,2024, '366P Clinicopathological predictors of favourable response to docetaxel in patients with metastatic castration-resistant prostate cancer', in Annals of Oncology, Elsevier BV, Vol. 35, pp. S1541 - S1541, http://dx.doi.org/10.1016/j.annonc.2024.10.385
,2024, 'AGITG MONARCC: A randomized phase 2 study of panitumumab monotherapy and panitumumab (pan) plus 5 fluorouracil (FU) as first-line therapy for RAS and BRAF wild type metastatic colorectal cancer—A trial by the Australasian Gastro-Intestinal Trials Group (AGITG).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 42, pp. 3535 - 3535, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3535
,2024, 'Cancer of Unknown Primary-Shining light into the unknown', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 20, pp. 108 - 109
,2024, 'This is Me: Revision of a co-designed resource to communicate what matters most to older adults with cancer when treatment decisions are being considered', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 20, pp. 214 - 215
,2024, 'Working towards equitable age-friendly care among older adults in regional cancer care', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 20, pp. 109 - 109
,2022, 'Regional Victorian trials alliance: Linkages, Innovation, Special populations, Equity (ReViTALISE) project: Addressing disparity in regional populations', in Asia Pacific Journal of Clinical Oncology, Wiley, Vol. 18, pp. 87 - 87, presented at COSA's 49th Annual Scientific Meeting, 02 November 2022 - 04 November 2022, https://onlinelibrary.wiley.com/doi/10.1111/ajco.13868
,2022, 'Solving unknown primary cancer - Earlier diagnosis (SUPER-ED): A stepped wedge cluster randomised controlled trial implementing a Model of Care to support earlier diagnosis', in Asia Pacific Journal of Clinical Oncology, Wiley, Vol. 18, pp. 143 - 144, presented at COSA's 49th Annual Scientific Meeting, 02 November 2022 - 04 November 2022, https://onlinelibrary.wiley.com/doi/10.1111/ajco.13869
,2022, 'Changing landscape of lung cancer survival in a regional Australian centre', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 160 - 160
,2022, 'Geriatric assessment (GA) in the instagram era: Adding photographs to electronic ga to enhance supportive care (ESC) of older adults with cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 224 - 224
,2022, 'Stigma and ageism - The challenges of delivering appropriate care to older adults with NSCLC', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 105 - 105
,2022, 'The utility of molecular tumour profiling for patients with advanced cancer in a regional Australian setting', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 151 - 151
,2021, 'Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.9543
,2021, 'Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)', in Gynecologic Oncology, Vol. 161, pp. 160 - 165, http://dx.doi.org/10.1016/j.ygyno.2021.02.016
,2020, 'MONARCC: A randomized phase II study of panitumumab monotherapy and panitumumab (pan) plus 5 Fluorouracil (FU) as first-line therapy for RAS and BRAF wild type metastatic colorectal cancer (mCRC): An AGITG clinical trial', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 38, presented at Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, CA, San Francisco, 23 January 2020 - 25 January 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000530922700257&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2019, 'Exercise and androgen deprivation therapy: Current practice and future direction at a regional cancer centre', in Asia Pacific Journal of Clinical Oncology, Wiley, Adelaide, pp. 198 - 198, presented at 2019 COSA 46th Annual Scientific Meeting, Adelaide, 12 November 2019 - 14 November 2019, http://dx.doi.org/10.1111/ajco.13263
,2019, 'Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: Experience of the first two years.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.3072
,2017, 'INCORPORATING GERI-ONCOLOGY ASSESSMENTS IN GU RESEARCH', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 13, pp. 39 - 39, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000427541700040&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2024, Whole genome sequencing improves tissue of origin diagnosis and treatment options for cancer of unknown primary, http://dx.doi.org/10.1101/2024.08.09.24311642
,2023, Association between Antihypertensive Medicine Use and Risk of Ovarian Cancer in Women Aged 50 Years and Older, http://dx.doi.org/10.2139/ssrn.4414764
,2022, DNA sequencing and gene-expression profiling assists in making a tissue of origin diagnosis in cancer of unknown primary, http://dx.doi.org/10.1101/2022.06.24.22276729
,